Subscribe to RSS
Vaccination Against Cervical Cancer in India: Our Children Deserve a Healthier Future
Cancer of the uterine cervix is the second most common cancer after breast cancer among Indian women.
About 604,127 women get this disease every year in the world and 56% of them die.
One woman in India dies every 8 minutes from cervical cancer.
It mainly affects young women belonging to the lower socioeconomic strata in the productive years of their lives (21–67 years of age).
The human papilloma virus (HPV) is responsible for the majority of cervical cancers and an effective vaccine is available against HPV.
Vaccination is most effective when given to young girls between the ages of 9 to 13 years before they become sexually active.
There is adequate evidence in the literature on the cost-effectiveness of HPV vaccination in preventing cervical cancer.
06 July 2021 (online)
© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; DOI: 10.3322/caac.21660.
- 2 Sankaranarayanan R, Basu P, Kaur P. et al. Current status of human papillomavirus vaccination in India’s cervical cancer prevention efforts. Lancet Oncol 2019; 20 (11) e637-e644
- 3 Chatterjee S, Chattopadhyay A, Samanta L, Panigrahi P. HPV and cervical cancer epidemiology - Current status of HPV vaccination in India. Asian Pac J Cancer Prev 2016; 17 (08) 3663-3673
- 4 Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006; 2006 (Suppl. 01) 40470
- 5 Mehrotra R, Hariprasad R, Rajaraman P. et al. Stemming the wave of cervical cancer: human papillomavirus vaccine introduction in India. J Glob Oncol 2018; 4: 1-4
- 6 Lei J, Ploner A, Elfström KM. et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383 (14) 1340-1348
- 7 Kaur P, Mehrotra R, Rengaswamy S. et al. Human papillomavirus vaccine for cancer cervix prevention: rationale & recommendations for implementation in India. Indian J Med Res 2017; 146 (02) 153-157
- 8 Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health 2014; 2 (07) e406-e414
- 9 Abbas KM, van Zandvoort K, Brisson M, Jit M. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. Lancet Glob Health 2020; 8 (04) e536-e544
- 10 Murthy V, Calcuttawala A, Chadha K. et al. Human papillomavirus in head and neck cancer in India: Current status and consensus recommendations. South Asian J Cancer 2017; 6 (03) 93-98
- 11 Ong KJ, Checchi M, Burns L, Pavitt C, Postma MJ, Jit M. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Sex Transm Infect 2019; 95 (01) 28-35
- 12 Center for Disease Control USA guidelines for HPV vaccination. Available at: https://www.cdc.gov/vaccines/vpd/hpv/hcp/administration.html. Accessed April 2, 2020
- 13 Deleré Y, Wichmann O, Klug SJ. et al. The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Dtsch Arztebl Int 2014; 111 (35/36) 584-591
- 14 Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev Vaccines 2018; 17 (12) 1085-1091
- 15 Drolet M, Bénard É, Pérez N, Brisson M. HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394 (10197) 497-509
- 16 Ogawa Y, Takei H, Ogawa R. Mihara K. Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies. J Pharm Health Care Sci 2017; 3: 18
- 17 Senapathy JG, Umadevi P, Kannika PS. The present scenario of cervical cancer control and HPV epidemiology in India: an outline. Asian Pac J Cancer Prev 2011; 12 (05) 1107-1115
- 18 Krishnamurthy A, Ramshankar V. Current status and future perspectives of molecular prevention strategies for cervical cancers. Indian J Surg Oncol 2020; 11 (04) 752-761
- 19 Srivastava AN, Misra JS, Srivastava S, Das BC, Gupta S. Cervical cancer screening in rural India: Status & current concepts. Indian J Med Res 2018; 148 (06) 687-696
- 20 Operational Framework, Management of Common Cancers. Ministry of Health and Family Welfare, Government of India. Available at: http://cancerindia.org.in/wp-content/uploads/2017/11/Operational_Framework_Management_of_Common_Cancers.pdf. Accessed March 18, 2021
- 21 Chauhan AS, Prinja S, Srinivasan R. et al. Cost effectiveness of strategies for cervical cancer prevention in India. PLoS One 2020; 15 (09) 0238291
- 22 Prinja S, Bahuguna P, Faujdar DS. et al. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India’s universal immunization program. Cancer 2017; 123 (17) 3253-3260
- 23 Diaz M, Kim JJ, Albero G. et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008; 99 (02) 230-238
- 24 Silas OA, Achenbach CJ, Murphy RL. et al. Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature. Expert Rev Vaccines 2018; 17 (01) 91-98
- 25 Das M. Cervical cancer vaccine controversy in India. Lancet Oncol 2018; 19 (02) e84
- 26 Cervical vaccine controversy in India. Available at: https://scroll.in/pulse/865284/efficacy-safety-cost-indias-decade-old-debate-on-the-cervical-cancer-vaccine-erupts-again. Accessed May 2, 2020
- 27 Gupta S, Kerkar RA, Dikshit R, Badwe RA. Is human papillomavirus vaccination likely to be a useful strategy in India?. South Asian J Cancer 2013; 2 (04) 193-197
- 28 Burger EA, Campos NG, Sy S, Regan C, Kim JJ. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine 2018; 36 (32 Pt A) 4823-4829
- 29 Laengsri V, Kerdpin U, Plabplueng C, Treeratanapiboon L, Nuchnoi P. Cervical cancer markers: epigenetics and microRNAs. Lab Med 2018; 49 (02) 97-111